Our findings provide references that routine clinical laboratory assays such as serum albumin and total bilirubin can be used to identify patients at higher risk of death while applying an advanced evaluation for NHL-sHLH patients. This evidence concerns the gene ALB and non-Hodgkin lymphoma.